Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 199

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 199
---
 the target award expressed as a percentage of each Table of Contents 2025 PROXY STATEMENT 38

NEO’s base salary and the actual award payment made in cash or cash equivalents to each of our NEOs based on their performance in fiscal 2024: Named Executive Officer Target Annual Incentive Award Opportunity (as a percentage of base salary) Achievement target bonus Actual Annual Incentive Award ($) Dr. Anzalone (1) 100% 120% $1,152,000 Mr. Myszkowski 45% 120% $314,496 Mr. O’Brien 45% 140% $378,000 Dr. Hamilton 45% 120% $314,496 Dr. San Martin (2) 45% —% $— Ms. Tracie Oliver (3) 40% —% $— (1) Dr. Anzalone received an initial bonus of $960,000, which was paid in December 2024 and an additional bonus of $192,000 which will be paid upon receipt of Hart Scott Rodino clearance of the Sarepta transaction. (2) Dr. San Martin left the Company on February 1, 2024 and did not receive an annual incentive award. (3) Ms. Oliver served as the Company's Chief Commercial Officer until October 2024 and did not receive an annual incentive award. The annual cash incentive award payments made to our NEOs for fiscal 2024 are set forth in the “Fiscal 2024 Summary Compensation Table” below. Long-Term Incentive Compensation We view long-term incentive compensation in the form of equity awards as a critical element of our executive compensation program. The realizable value of these equity awards over time bears a direct relationship to our stock price, and, therefore, these awards are an incentive for our executive officers, including our NEOs, to create value for our stockholders. Equity awards also help us retain qualified executive officers in a competitive market. Long-term incentive compensation opportunities in the form of equity awards are granted to our executive officers by the Compensation Committee. The amount and forms of such equity awards are determined by the Compensation Committee after considering the factors described in “Governance of Executive Compensation Program — Compensation-Setting Process” above. 2024 Long-Term Incentive Awards Performance-Based RSU Award for Chief Executive Officer Annual equity awards granted to our executive officers are solely in the form of RSU awards that may be settled for shares of our common stock. Our CEO's